Osteoporosis News

A report from the National Osteoporosis Foundation details fracture rates for all 50 U.S. states and highlights ethnic and racial disparities among Medicare beneficiaries for hospitalization, mortality and health costs.

The use of denosumab to treat osteoporosis has increased rapidly since its FDA approval in 2010, and it is now the second most used medication after alendronate, according to data presented at the ENDO annual meeting.

Founder of India’s first bone density and osteoporosis service, Ambrish Mithal, MD, DM, played a key role in establishing osteoporosis as a serious national health problem.

Osteoporosis, long considered a disease of older age, is estimated to affect about 25% of women aged at least 65 years, according to the CDC.

Adults with osteoporosis have had fewer in-person appointments, delayed DXA scans and interruptions with medication supplies during the COVID-19 pandemic, according to results from a global survey of physicians.

The FDA granted breakthrough device designation to a belt that uses proprietary vibration technology to stop the progression of bone loss and prevent the onset of osteoporosis, according to an industry press release.

Healio LIVE announced Orthopedics Today Hawaii 2021, which was scheduled for January 2021 in Maui, Hawaii, will be rescheduled to later in the year.

Among patients using long-term glucocorticoids, denosumab is superior to alendronate in increasing bone mineral density in the spine after 1 year, according to a speaker at ACR Convergence 2020.

Less than 3% of older men who had experienced an osteoporosis-related fracture had been properly diagnosed and treated, according to findings presented at ACR Convergence 2020.

Romosozumab as a first treatment produces ‘substantial gains’ in hip and lumbar spine bone mineral density within 1 year, a result that is augmented by then transitioning to a potent antiresorptive, according to a study.